Self-powered paper-based 'SPEDs' may lead to new medical-diagnostic tools

A new medical-diagnostic device made out of paper detects biomarkers and identifies diseases by performing electrochemical analyses - powered only by the user's touch - and reads out the color-coded test results, making it easy for non-experts to understand. The self-powered, paper-based electrochemical devices, or SPEDs, are designed for sensitive diagnostics at the "point-of-care," or when care is delivered to patients, in regions where the public has limited access to resources or sophisticated medical equipment.

"You could consider this a portable laboratory that is just completely made out of paper, is inexpensive and can be disposed of through incineration," said Ramses V. Martinez, an assistant professor of industrial and biomedical engineering at Purdue University. "We hope these devices will serve untrained people located in remote villages or military bases to test for a variety of diseases without requiring any source of electricity, clean water, or additional equipment."

"SPEDs are inexpensive, lightweight, flexible and easy to use," Martinez said.

Research findings are detailed in a paper appearing on Aug. 22 in Advanced Materials Technologies.

The test is initiated by placing a pinprick of blood in a circular feature on the device, which is less than two-inches square. SPEDs also contain "self-pipetting test zones" that can be dipped into a sample instead of using a finger-prick test.

The top layer of the SPED is fabricated using untreated cellulose paper with patterned hydrophobic "domains" that define channels that wick up blood samples for testing. These "micro?uidic channels" allow for accurate assays that change color to indicate specific testing results. A machine-vision diagnostic application also was created to automatically identify and quantify each of these "colorimetric" tests from a digital image of the SPED, perhaps taken with a cellphone, to provide fast diagnostic results to the user and to facilitate remote-expert consultation.

The bottom layer of the SPED is a "triboelectric generator," or TEG, which generates the electric current necessary to run the diagnostic test simply by rubbing or pressing it. The researchers also designed an inexpensive handheld device called a potentiostat, which is easily plugged into the SPED to automate the diagnostic tests so that they can be performed by untrained users. The battery powering the potentiostat can be recharged using the TEG built into the SPEDs.

"To our knowledge, this work reports the ?rst self-powered, paper-based devices capable of performing rapid, accurate, and sensitive electrochemical assays in combination with a low-cost, portable potentiostat that can be recharged using a paper-based TEG," Martinez said.

He co-authored the paper with graduate students Aniket Pal and Debkalpa Goswami; visiting scholars Hugo E. Cuellar and Heloisa F. N. Caurin; and Randy Kuang, a high school student who participated in the research.

The research paper describes the SPEDs, the portable potentiostat and a machine-vision algorithm that is able to recognize the color-coded information. SPEDs are compatible with mass-printing technologies, such as roll-to-roll printing or spray deposition. They can perform "multiplexed" analyses enabling the highly sensitive and accurate detection of various targets for a range of point-of-care testing applications. And they can be used to power other electronic devices to facilitate telemedicine applications in resource-limited settings.

The SPEDs were used to detect biomarkers such as glucose, uric acid and L-lactate, ketones, and white blood cells, which indicate factors related to liver and kidney function, malnutrition and anemia. Future versions of the technology will contain several additional layers for more complex assays to detect diseases such as dengue fever, yellow fever, malaria, HIV and hepatitis, Martinez said.

Aniket Pal, Hugo E Cuellar, Randy Kuang, Heloisa F N Caurin, Debkalpa Goswami, Ramses V Martinez.
Self-Powered, Paper-Based Electrochemical Devices for Sensitive Point-of-Care Testing.
Adv. Mater. Technol. 2017, 1700130. doi: 10.1002/admt.201700130.

Most Popular Now

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...